

Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China - a multicentre retrospective study

Lihui Wen¹, Ziyang Chen¹, Ziyi Jin¹, Wenyong Pan², Lin Liu³, Min Wu⁴, Fuwan Ding⁵, Huaixia Hu⁶, Xiang Ding⁷, Hua Wei⁸, Yaohong Zou⁹, Xian Qian¹⁰, Meimei Wang¹¹, Jian Wu¹², Juan Tao¹³, Jun Tan¹⁴, Zhanyun Da¹⁵, Miaoja Zhang¹⁶, Jing Li¹⁷, Xuebing Feng¹, Jun Liang^{*1}, Huayong Zhang^{*1}, Lingyun Sun¹

1. Department of Rheumatology and Immunology, Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Nanjing, China
2. Department of Rheumatology, Huai'an First People's Hospital, Huai'an, China
3. Department of Rheumatology, Xuzhou Central Hospital, Xuzhou, China
4. Department of Rheumatology, Third Affiliated Hospital of Soochow University, Changzhou, China
5. Department of Endocrinology, Yancheng Third People's Hospital, Yancheng, China
6. Department of Rheumatology, Lianyungang Second People's Hospital, Lianyungang, China
7. Department of Rheumatology, Lianyungang First People's Hospital, Lianyungang, China
8. Department of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, China
9. Department of Rheumatology, Wuxi People's Hospital, Wuxi, China
10. Department of Rheumatology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China
11. Department of Rheumatology, Southeast University Zhongda Hospital, Nanjing, China
12. Department of Rheumatology, First Affiliated Hospital of Soochow

University, Suzhou, China

13. Department of Rheumatology, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, China

14. Department of Rheumatology, Zhenjiang First People's Hospital, Zhenjiang, China

15. Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, China

16. Department of Rheumatology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China

17. Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China

Correspondence to:

Huayong Zhang. Department of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing 210008, China. Email: huayong.zhang@nju.edu.cn.

Jun Liang. Department of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing 210008, China. Email: 13505193169@139.com.

Lihui Wen and Ziyang Chen contributed equally to this work.

Supplementary Table 1. Detailed organ damages on admission among different age-onset groups

<i>Organ damage on admission</i>	All (n=797)	JSLE^a (n=88)	ASLE^b (n=638)	LSLE^c (n=71)	P
<i>Ocular</i>	2 (0.3)	1 (1.1)	1 (0.2)	0 (0.0)	0.359
Any cataract ever	1 (0.1)	1 (1.1)	0 (0.0)	0 (0.0)	0.199
Retinal change or optic atrophy	1 (0.1)	0 (0.0)	1 (0.2)	0 (0.0)	1.000
<i>Neuropsychiatric</i>	18 (2.3)	1 (1.1)	15 (2.4)	2 (2.8)	0.823
Cognitive impairment	12 (1.5)	0 (0.0)	12 (1.9)	0 (0.0)	0.242
Seizures requiring therapy for 6 months	3 (0.4)	1 (1.1)	2 (0.3)	0 (0.0)	0.488
Cerebrovascular accident ever	4 (0.5)	0 (0.0)	2 (0.3)	2 (2.8)	0.047
Cranial or peripheral neuropathy	1 (0.1)	0 (0.0)	0 (0.0)	1 (1.4)	0.089
<i>Renal</i>	85 (10.7)	11 (12.5)	65 (10.2)	9 (12.7)	0.703
Estimated or measured glomerular filtration rate <50%	20 (2.5)	3 (3.4)	16 (2.5)	1 (1.4)	0.772
Proteinuria \geq 3.5 gm/24 hours	67 (8.4)	9 (10.2)	52 (8.2)	6 (8.5)	0.805
End-stage renal disease	22 (2.8)	6 (6.8)	12 (1.9)	4 (5.6)	0.016
<i>Pulmonary</i>	19 (2.4)	0 (0.0)	15 (2.4)	4 (5.6)	0.060
Pulmonary fibrosis	12 (1.5)	0 (0.0)	10 (1.6)	2 (2.8)	0.338
Shrinking lung	7 (0.9)	0 (0.0)	4 (0.6)	3 (4.2)	0.023
Pulmonary infarction	2 (0.3)	0 (0.0)	2 (0.3)	0 (0.0)	1.000
<i>Cardiovascular</i>	16 (2.0)	0 (0.0)	16 (2.5)	0 (0.0)	0.161

Valvular disease	2 (0.3)	0 (0.0)	2 (0.3)	0 (0.0)	1.000
Pericarditis for 6 months/pericardiectomy	14 (1.8)	0 (0.0)	14 (2.2)	0 (0.0)	0.162
<i>Peripheral vascular</i>	3 (0.4)	0 (0.0)	2 (0.3)	1 (1.4)	0.275
Minor tissue loss (pulp space)	1 (0.1)	0 (0.0)	1 (0.2)	0 (0.0)	1.000
Venous thrombosis with swelling/ulceration/venous stasis	2 (0.3)	0 (0.0)	1 (0.2)	1 (1.4)	0.182
<i>Gastrointestinal</i>	3 (0.4)	0 (0.0)	3 (0.5)	0 (0.0)	1.000
Infarction or resection of bowel below duodenum, spleen, liver, or gall bladder	2 (0.3)	0 (0.0)	2 (0.3)	0 (0.0)	1.000
Mesenteric insufficiency	1 (0.1)	0 (0.0)	1 (0.2)	0 (0.0)	1.000
<i>Musculoskeletal</i>	20 (2.5)	1 (1.1)	16 (2.5)	3 (4.2)	0.486
Muscle atrophy or weakness	4 (0.5)	1 (1.1)	3 (0.5)	0 (0.0)	0.590
Deforming or erosive arthritis	16 (2.0)	0 (0.0)	13 (2.0)	3 (4.2)	0.158
<i>Skin</i>	18 (2.3)	0 (0.0)	17 (2.7)	1 (1.4)	0.209
Scarring chronic alopecia	16 (2.0)	0 (0.0)	15 (2.4)	1 (1.4)	0.291
Extensive scarring or panniculum other than scalp and pulp space	2 (0.3)	0 (0.0)	1 (0.2)	1 (1.4)	0.120
Skin ulceration (excluding thrombosis) for >6 months	2 (0.3)	0 (0.0)	2 (0.3)	0 (0.0)	1.000
<i>Premature gonadal failure</i>	8 (1.0)	2 (2.3)	6 (0.9)	0 (0.0)	0.289
<i>SDI^d ≥1 on admission (%)</i>	114 (14.3)	12 (13.6)	88 (13.8)	14 (19.7)	0.393

^aJSLE, juvenile-onset SLE; ^bASLE, adult-onset SLE; ^cLSLE, late-onset SLE;

^dSDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.

Supplementary Table 2. Detailed cardiopulmonary involvement on admission among different age-onset groups

<i>Cardiopulmonary involvement on admission</i>	All (n=797)	JSLE ^a (n=88)	ASLE ^b (n=638)	LSLE ^c (n=71)	P
Myocarditis	13 (1.6)	1(1.1)	12 (1.9)	0(0)	0.459
Serositis	141(17.7)	8(9.1)	119(18.7)	14(19.7)	0.079
Interstitial lung disease	36(4.5)	2(2.3)	25(3.9)	9(12.7)	0.002
Others	20(2.5)	1(1.1)	17(2.7)	2(2.8)	0.681

^aJSLE, juvenile-onset SLE; ^bASLE, adult-onset SLE; ^cLSLE, late-onset SLE.